Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fluoxetine

L Gram1

  • 1Department of Clinical Pharmacology, Odense University, Denmark.

The New England Journal of Medicine
|November 17, 1994
PubMed
Summary
This summary is machine-generated.

Fluoxetine is an effective antidepressant compared to placebo, but its optimal dose is unknown. It may be less effective for severe depression and is best for moderate cases, with alternative treatments recommended if ineffective after six weeks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative assessment of Vibrio virulence in marine fish larvae.

Journal of fish diseases·2017
Same author

Biofilm formation is not a prerequisite for production of the antibacterial compound tropodithietic acid in Phaeobacter inhibens DSM17395.

Journal of applied microbiology·2014
Same author

Control of bacterial disease in cultures of marine larvae and live feed organisms by a probiotic bacterium.

Communications in agricultural and applied biological sciences·2014
Same author

Trends in Anti-epileptic Drug Development.

Behavioural neurology·2014
Same author

Progress in the medical treatment of epilepsy: an overview of new antiepileptic drugs.

European journal of neurology·2013
Same author

Disruption of cell-to-cell signaling does not abolish the antagonism of Phaeobacter gallaeciensis toward the fish pathogen Vibrio anguillarum in algal systems.

Applied and environmental microbiology·2013
Same journal

Ebola at 50 - Lessons for Outbreak Response and Preparedness.

The New England journal of medicine·2026
Same journal

Ianalumab plus Eltrombopag in Immune Thrombocytopenia. Reply.

The New England journal of medicine·2026
Same journal

Ianalumab plus Eltrombopag in Immune Thrombocytopenia.

The New England journal of medicine·2026
Same journal

Hypertension Control in Low-Income Patients. Reply.

The New England journal of medicine·2026
Same journal

Hypertension Control in Low-Income Patients.

The New England journal of medicine·2026
Same journal

Hypertension Control in Low-Income Patients.

The New England journal of medicine·2026
See all related articles

Area of Science:

  • Pharmacology
  • Psychiatry
  • Clinical Medicine

Background:

  • Fluoxetine is a widely used antidepressant.
  • Its efficacy relative to placebo and other antidepressants requires further clarification.
  • A clear dose-effect relationship has not been established.

Purpose of the Study:

  • To review the efficacy and safety of fluoxetine as an antidepressant.
  • To compare fluoxetine with tricyclic antidepressants and placebo.
  • To identify appropriate patient populations and treatment durations for fluoxetine.

Main Methods:

  • Review of published studies on fluoxetine's antidepressant effects.
  • Comparison of fluoxetine's efficacy and side effect profile with other antidepressants.
  • Analysis of safety data, including drug interactions and overdose effects.

Related Experiment Videos

Main Results:

  • Fluoxetine is more effective than placebo.
  • Its efficacy is comparable to tricyclic antidepressants, but it may be less effective for severe inpatient depression.
  • Fluoxetine has a favorable side effect profile with fewer anticholinergic, hypotensive, and sedative effects than tricyclics.
  • Common side effects include nausea, anorexia, insomnia, and nervousness.

Conclusions:

  • Fluoxetine is a suitable option for outpatients with moderate depression.
  • Alternative treatments should be considered if no improvement is observed within four to six weeks.
  • Fluoxetine's popularity may stem from broader mood-modulating effects beyond depression biology.